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A B S T R A C T
Background
Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease. The disease is relatively common
among people with decompensated cirrhosis. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood
vessels. The previous version of this systematic review found a potential beneficial effect of terlipressin on mortality and renal function
in people with cirrhosis and hepatorenal syndrome.
Objectives
To assess the beneficial and harmful effects of terlipressin versus placebo/no intervention for people with cirrhosis and hepatorenal
syndrome.
Search methods
We identified eligible trials through searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central
Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase, and Science Citation Index Expanded, and
manual searches until 21 November 2016.
Selection criteria
Randomised clinical trials (RCTs) involvingparticipantswith cirrhosis and type 1 or type 2hepatorenal syndrome allocated to terlipressin
versus placebo or no intervention. We allowed co-administration with albumin administered to both comparison groups.
Data collection and analysis
Two review authors independently extracted data from trial reports and undertook correspondence with the authors. Primary outcomes
were mortality, hepatorenal syndrome, and serious adverse events. We conducted sensitivity analyses of RCTs in which participants
received albumin, subgroup analyses of participants with type 1 or type 2 hepatorenal syndrome, and Trial Sequential Analyses to
control random errors. We reported random-effects meta-analyses with risk ratios (RR) and 95% confidence intervals (CI). We assessed
the risk of bias based on the Cochrane Hepato-Biliary Group domains. We graded the quality of the evidence using GRADE.
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Main results
We included nine RCTs with a total of 534 participants with cirrhosis and ascites. One RCT had a low risk of bias for mortality and
a high risk of bias for the remaining outcomes. All included trials had a high risk of bias for non-mortality outcomes. In total, 473
participants had type 1 hepatorenal syndrome. Seven RCTs specifically evaluated terlipressin and albumin. Terlipressin was associated
with a beneficial effect on mortality when including all RCTs (RR 0.85, 95% CI 0.73 to 0.98; 534 participants; number needed to
treat for an additional beneficial outcome (NNTB) 10.3 people; low-quality evidence). Trial Sequential Analysis including all RCTs
also found a beneficial effect of terlipressin. Additional analyses showed a beneficial effect of terlipressin and albumin on reversal of
hepatorenal syndrome (RR 0.63, 95% CI 0.48 to 0.82; 510 participants; 8 RCTs; NNTB 4 people; low-quality evidence). Terlipressin
increased the risk of serious cardiovascular adverse events (RR 7.26, 95% CI 1.70 to 31.05; 234 participants; 4 RCTs), but it had no
effect on the risk of serious adverse events when analysed as a composite outcome (RR 0.91, 95% CI 0.68 to 1.21; 534 participants; 9
RCTs; number needed to treat for an additional harmful outcome 24.5 people; low-quality evidence). Non-serious adverse events were
mainly gastrointestinal, including diarrhoea (RR 5.76, 95% CI 2.19 to 15.15; 240 participants; low-quality evidence) and abdominal
pain (RR 1.54, 95% CI 0.97 to 2.43; 294 participants; low-quality evidence).
We identified one ongoing trial on terlipressin versus placebo in participants with cirrhosis, ascites, and hepatorenal syndrome type 1.
Three RCTs reported funding from a pharmaceutical company. The remaining trials did not report funding or did not receive funding
from pharmaceutical companies.
Authors’ conclusions
This review suggests that terlipressin may be associated with beneficial effects on mortality and renal function in people with cirrhosis
and type 1 hepatorenal syndrome, but it is also associated with serious adverse effects. We downgraded the strength of the evidence due
to methodological issues including bias control, clinical heterogeneity, and imprecision. Consequently, additional evidence is needed.
P L A I N L A N G U A G E S U M M A R Y
Terlipressin versus placebo/no intervention for people with cirrhosis and hepatorenal syndrome
Background
Cirrhosis is a chronic disorder of the liver where scar tissue replaces the normal liver. People with cirrhosis can develop a kidney disease
known as hepatorenal syndrome. The disease may develop when the blood flow to the kidneys becomes insufficient. Increasing the
blood flow to the kidneys may therefore benefit people with hepatorenal syndrome. There are two types of hepatorenal syndrome: type
1 occurs rapidly, and type 2 has a slower onset. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood
vessels. The drug may therefore help people with cirrhosis and hepatorenal syndrome.
Review question
Is terlipressin better than inactive placebo/no treatment for people with hepatorenal syndrome?
Search date
November 2016.
Study characteristics
The review includes nine randomised clinical trials (RCTs) and a total of 534 participants. The trials originated from six countries.
Seven trials included only participants with type 1 hepatorenal syndrome. Two trials included a total of 96 participants with type 1 or
type 2 hepatorenal syndrome.
Study funding sources
Three RCTs reported funding from a pharmaceutical company. The remaining trials did not report funding or did not receive funding
from pharmaceutical companies.
Key results
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People who received terlipressin had a lower risk of dying than people who received inactive placebo or no treatment. Terlipressin was
also associated with a beneficial effect on renal function. Terlipressin increased the risk of serious circulation and heart problems (so-
called cardiovascular events). Other adverse events included diarrhoea and abdominal pain.
The analyses mainly included people with type 1 hepatorenal syndrome. No beneficial or harmful effects of terlipressin were found
when analysing participants with type 2 hepatorenal syndrome (possibly due to the small number of participants).
Quality of the evidence
We considered the evidence to be of low quality.
3Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Terlipressin versus placebo or no intervention for hepatorenal syndrome. Administration of albumin allowed if administered to both the intervention and comparison group
Patient or population: people with hepatorenal syndrome
Setting: hospital
Intervention: terlipressin alone or terlipressin plus albumin
Comparison: placebo or no intervent ion or albumin
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo or no
intervention
Risk with terlipressin
Mortality Study populat ion RR 0.85 (0.73 to 0.98) 534
(9 RCTs)
⊕⊕©©
LOW1
Downgraded because
of i) clinical hetero-
geneity and ii) the re-
sults of the Trial Se-
quent ial Analysis
688 per 1000 536 per 1000
(433 to 660)
Moderate
625 per 1000 488 per 1000
(394 to 600)
Hepatorenal syndrome Study populat ion RR 0.63 (0.48 to 0.82) 510
(7 RCTs)
⊕⊕©©
LOW
Downgraded because
of i) clinical hetero-
geneity and ii) all t rials
are judged as ’high risk
of bias’
879 per 1000 510 per 1000
(431 to 606)
Moderate
875 per 1000 507 per 1000
(429 to 604)
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Serious adverse events Study populat ion RR 0.91 (0.68 to 1.21) 534 (9 RCTs) ⊕⊕©©
LOW
Downgraded because
of i) clinical hetero-
geneity and ii) all RCTs
are judged as high risk
of bias
85 per 1000 212 per 1000
(131 to 344)
Serious cardiovascular
adverse events
Study populat ion RR 7.26 (1.70 to 31.05) 234
(4 RCTs)
⊕⊕©©
LOW
Downgraded because
of i) clinical hetero-
geneity and ii) all RCTs
are judged as high risk
of bias16 per 1000 111 per 1000
Abdominal pain Study populat ion RR 1.54 (0.97 to 2.43) 294 (4 RCTs) ⊕⊕©©
LOW1
Downgraded because
of i) clinical hetero-
geneity and ii) all RCTs
are judged as high risk
of bias149 per 1000 229 per 1000
Diarrhoea Study populat ion RR 5.76 (2.19 to 15.15) 240 (2 RCTs) ⊕⊕©©
LOW
Downgraded because
of i) clinical hetero-
geneity and ii) all RCTs
are judged as high risk
of bias33 per 1000 190 per 1000
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Not conf irmed in analyses of randomised clinical trials (RCTs) with a low risk of bias.
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B A C K G R O U N D
Description of the condition
Hepatorenal syndrome is a potentially reversible renal failure asso-
ciated with severe liver disease (Arroyo 1996). The disease is rela-
tively common among people with decompensated cirrhosis. Over
20% of people with decompensated cirrhosis become hospitalised
with renal failure, among whom up to 20% have hepatorenal syn-
drome (Gines 1993; Garcia-Tsao 2008; Israelsen 2015b). The di-
agnosis includes cirrhosis and ascites plus impaired renal function
after exclusion of parenchymal renal disease and factors that may
precipitate renal dysfunction in cirrhosis (Salerno 2007). Hepa-
torenal syndrome is divided into two types, with type 1 having
the most rapid course of development. Without treatment, type
1 has a median survival of about two weeks and type 2 a median
survival of about six months (Arroyo 1996; Gines 2003; Salerno
2007).
Description of the intervention
The development of hepatorenal syndrome is associated with the
circulatory changes seen in cirrhosis of the liver subsequent to
portal hypertension and vasodilation of the splanchnic vasculature
(Cardenas 2003). This vasodilation results in effective underfilling
of the renal arteries and activation of the renin-angiotensin-aldos-
terone, the arginine-vasopressin, and the sympathetic nervous sys-
tems (Pasqualetti 1998; Moller 2004; Ruiz del Arbol 2005). Acti-
vation of these systems may in turn lead to severe vasoconstriction
of the renal arteries and hepatorenal syndrome (Cardenas 2003).
Current treatments focus on improvement of renal blood flow and
effective arterial circulation. This is done with volume expanders
(such as intravenous albumin) or with vasoactive drugs that pref-
erentially constrict the splanchnic circulation, such as terlipressin.
How the intervention might work
Vasoactive drugs that increase the splanchnic arterial tone may
reverse hepatorenal syndrome. Vasopressin is a potential candi-
date, but may lead to severe ischaemia of the mesenteric mucosa,
skin, and myocardium (Obritsch 2004). A controlled trial found
that the vasopressin analogue terlipressin may be a safer alternative
(Freeman 1982). Terlipressin is administered intravenously either
by bolus or continuous infusion. It is commonly titrated based
on desired change in mean arterial pressure. It has both systemic
and splanchnic constrictive effects, so adverse events include se-
quelae of vasoconstriction, such asmild gastrointestinal symptoms
(e.g. diarrhoea and abdominal pain) or more severe evidence of
ischaemia.
Why it is important to do this review
Two initial randomised clinical trials (RCTs) evaluated terlipressin
for participants with hepatorenal syndrome; however, they were
small and had short-term follow-up (Hadengue 1998; Solanki
2003). Three subsequent larger RCTs found no convincing ef-
fects on mortality (Martín-Llahí 2008; Neri 2008; Sanyal 2008).
Three meta-analyses of RCTs and observational studies reached
equivocal findings (Fabrizi 2009; Dobre 2010; Sagi 2010). In the
previous version of this systematic review, we found a potential
beneficial effect of terlipressin on mortality and reversal of hepa-
torenal syndrome (Gluud 2006), but we also identified potential
methodological concerns. We updated the review to include the
currently available evidence.
O B J E C T I V E S
To assess the beneficial and harmful effects of terlipressin versus
placebo or no intervention for people with cirrhosis and hepatore-
nal syndrome.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs irrespective of blinding, publication status,
or language. We included the first period from cross-over RCTs.
In addition, we planned to include quasi-randomised studies and
observational studies in our assessment of serious adverse events
(Higgins 2011), although this is a known limitation making us
focus more on benefits than on harms (Gluud 2017).
Types of participants
We included people with cirrhosis and type 1 or type 2 hepatore-
nal syndrome (defined as an increase in creatinine in people with
ascites and no other causes of renal disease).
Types of interventions
We included RCTs comparing terlipressin (any dose or duration)
versus placebo or no intervention. We allowed co-administration
of albumin given to both comparison groups.
Types of outcome measures
We assessed all outcomes at the maximum duration of follow-up.
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Primary outcomes
1. Mortality.
2. Hepatorenal syndrome (number of participants who did
not achieve reversal of hepatorenal syndrome).
3. Serious adverse events: any untoward medical occurrence
that led to death, was life-threatening, or required hospitalisation
or prolongation of hospitalisation (ICH-GCP 1997). We
analysed serious adverse events as a composite outcome (Gluud
2017).
Secondary outcomes
1. Health-related quality of life: the overall score based on the
quality of life questionnaires used in individual trials.
2. Non-serious adverse events: all adverse events that did not
fulfil the criteria for serious adverse events.
Search methods for identification of studies
Electronic searches
We performed electronic searches in the Cochrane Hepato-Biliary
Group Controlled Trials Register, the Cochrane Central Register
of Controlled Trials (CENTRAL) in theCochrane Library, MED-
LINE (OvidSP), Embase (OvidSP), and Science Citation Index
Expanded (Web of Science) (Royle 2003). The search strategies
with the timespan of the searches are given in Appendix 1. We
updated searches as of 21 November 2016.
Searching other resources
Manual searches included scanning of reference lists in relevant
articles and conference proceedings. We also searched trial regis-
ters through the World Health Organization International Clin-
ical Trials Registry Platform (WHO ICTRP) search portal (
www.who.int/ictrp/search/en/) (21 November, 2016).
Data collection and analysis
Selection of studies
Two review authors (AA and MI) independently selected trials
eligible for inclusion from the updated literature searches and listed
excluded with the reasons for exclusion.
Data extraction and management
Two review authors (AA and MI) independently extracted data.
All disagreements were resolved through discussion before analy-
ses. In case of disagreements, a third review author (LG) acted as
ombudsman. We wrote to authors of the included trials to obtain
additional information not described in the published reports, in-
cluding missing data.
Assessment of risk of bias in included studies
We assessed the risk of bias using the domains described in the
Cochrane Hepato-Biliary Group Module (Gluud 2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: not specified.
• High risk of bias: the sequence generation was not random.
We planned to include such studies for assessment of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: i) the outcome was mortality, which
according to previous empirical evidence is not likely to be
influenced by lack of blinding (Hróbjartsson 2001; Savovi
2012); or ii) blinding of participants and key study personnel
ensured, and it is unlikely that the blinding could have been
broken.
• Unclear risk of bias: insufficient information to permit
judgement of ‘low risk’ or ‘high risk’.
• High risk of bias: no blinding or incomplete blinding, and
the outcome is likely to be influenced by lack of blinding (non-
mortality outcomes).
Blinding of outcome assessors
• Low risk of bias: i) the outcome was mortality, which
according to previous empirical evidence is not likely to be
influenced by lack of blinding (Hróbjartsson 2001; Savovi
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2012); or ii) blinding of outcome assessment ensured, and it is
unlikely that the blinding could have been broken.
• Unclear risk of bias: insufficient information to permit
judgement of ‘low risk’ or ‘high risk’.
• High risk of bias: no blinding or inadequate blinding (e.g.
intravenous versus orally administered drugs), and the outcome
is likely to be influenced by lack of blinding (non-mortality
outcomes).
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The investigators
used sufficient methods, such as intention-to-treat analyses with
multiple imputations or carry-forward analyses, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data induced bias on the results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported clinically relevant
outcomes (mortality, hepatic encephalopathy, and serious adverse
events). If we had access to the original trial protocol, the
outcomes should have been those called for in that protocol. If
we obtained information from a trial registry (such as
www.clinicaltrials.gov), we only used the information if the
investigators registered the trial before inclusion of the first
participant.
• Unclear risk of bias: predefined outcomes were not reported
fully.
• High risk of bias: one or more predefined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support.
• Unclear risk of bias: no information on clinical trial support
or sponsorship was available.
• High risk of bias: the trial was sponsored by industry,
received support in the form of terlipressin or placebo, or
received any other type of support.
Other bias
• Low risk of bias: the trial appeared to be free of other biases
including medicinal dosing problems or follow-up (as defined
below).
• Unclear risk of bias: the trial may or may not have been free
of other factors that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias, such as the administration of
inappropriate treatments to the controls (e.g. an inappropriate
dose) or follow-up (e.g. the trial included different follow-up
schedules for participants in the allocation groups), or premature
discontinuation of the trial.
Overall bias assessment
• Low risk of bias: all domains were classified as low risk of
bias using the definitions described above.
• High risk of bias: one or more of the bias domains were
classified as unclear or high risk of bias.
Measures of treatment effect
We expressed outcomes using risk ratios (RR) with 95% confi-
dence intervals (CI). For primary outcomes, we calculated the
number needed to treat (NNT) using the inverse of the risk dif-
ference (RD). Based on the control group event rate, we repeated
the analyses using odds ratios (OR) and RD. The analyses using
OR and RD had no influence on the results of the review.
Unit of analysis issues
We included data from the first treatment period of cross-over
trials.
Dealing with missing data
We planned to evaluate the importance of missing data in a worst-
case scenario analysis (with inclusion of missing outcomes as treat-
ment failures) and an extreme worst-case scenario analysis (includ-
ing missing outcomes as failures in the experimental group and
successes in the control group). However, we did not identify par-
ticipants with missing outcome data and were therefore unable to
conduct these analyses.
Assessment of heterogeneity
We expressed heterogeneity as I2 values using the following thresh-
olds: 0% to40%(unimportant), 40 to 60%(moderate), 60 to 80%
(substantial), and > 80% (considerable). We have included this
information in the ’Summary of findings’ tables (GRADEpro).
Assessment of reporting biases
For meta-analyses with at least 10 RCTs, we planned to assess
reporting biases through regression analyses.
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Data synthesis
We performed the analyses in ReviewManager 5 (RevMan 2014),
STATA (STATA), and Trial Sequential Analysis (TSA 2011), and
used GRADEpro softwareto prepare ’Summary of findings’ tables
(GRADEpro).
Meta-analysis
We initially conducted fixed-effect and random-effects meta-anal-
yses (Higgins 2011). If the estimates of the fixed-effect and ran-
dom-effects meta-analyses were similar, then we assumed that any
small-study effects had little effect on the intervention effect es-
timate. If the random-effects estimate was more beneficial, we
planned to re-evaluate whether it was reasonable to conclude that
the intervention was more effective in the smaller studies. We orig-
inally planned to evaluate if the larger RCTs tended to be con-
ducted with greater methodological rigour, or conducted in cir-
cumstances more typical of the use of terlipressin in clinical prac-
tice. Had we found this scenario, we planned to report the results
of meta-analyses restricted to the larger, more rigorous studies.
However, this scenario did not occur.
Based on the expected clinical heterogeneity, we expected that a
number of analyses would display statistical heterogeneity (I2 >
0%). For random-effects models, precision will decrease with in-
creasing heterogeneity and confidence intervals will widen corre-
spondingly. We therefore expected that the random-effects model
would give the most conservative (and a more correct) estimate of
the intervention effect. Accordingly, we have reported the results
of our analyses based on random-effects meta-analyses.
Trial Sequential Analysis
We performedTrial Sequential Analysis to control the risks of type
1 and type 2 errors and to evaluate futility in the assessment of
our primary outcomes (TSA 2011; Gluud 2017). We defined the
required information size (also known as the diversity-adjusted
required information size) as the number of participants needed
to detect or reject an intervention effect based on the relative risk
reduction (RRR) and control group risk (CGR). Firm evidence
was established if the Z-curve crossed the monitoring boundary
(also known as the trial sequential monitoring boundary) before
reaching the required information size. Based on previous evidence
(Krag 2008), we performed the analyses with alpha set to 3%,
power to 90%, and the RRR, CGR, and heterogeneity correction
to 25%, 61.5%, and 30% for mortality; 25%, 87.5%, and 70%
for hepatorenal syndrome; and 25%, 15%, and 20% for serious
cardiovascular adverse events. We repeated the analyses with the
RRR reduced to 20% for mortality, hepatorenal syndrome, and
serious cardiovascular adverse events. In the analyses of serious
cardiovascular events, we also reduced the CGR to 5%.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses to investigate heterogeneity as-
sociated with the type of hepatorenal syndrome and use of albu-
min.
Sensitivity analysis
We did not evaluate the influence of bias because only one RCT
was at low risk of bias for mortality and no randomised clinical
trials were at low risk of bias for the remaining outcomes.
Summary of findings tables
We used GRADEpro to generate a ’Summary of findings’ table
with information about outcomes, risk of bias, and the results of
the meta-analyses (GRADEpro). We used the GRADE system to
evaluate the quality of the evidence for outcomes reported in the
review considering the within-study risk of bias (methodological
quality), indirectness of evidence, heterogeneity, imprecision of
effect estimate, and risk of publication bias.
R E S U L T S
Description of studies
We included nine randomised clinical trials in the quantitative
and qualitative analyses (see Characteristics of included studies).
We also identified one ongoing trial (NCT01143246).
Results of the search
The electronic searches revealed 619 potentially eligible references
and the manual searches three additional references (Figure 1).
After scanning the titles and abstracts, we retrieved and listed 25
records. We had to exclude 10 of these that referred to randomised
clinical trials on participants with hepatorenal syndrome because
they did not evaluate the interventions assessed in the present
review (Chelarescu 2003; Pomier 2003; Alessandria 2007; Angeli
2008; Sharma 2008; Silawat 2011; Cavallin 2012; Indrabi 2013;
Wan 2014; Cavallin 2015; Nguyen-Tat 2015). The remaining
references referred to nine RCTs that fulfilled our inclusion criteria
(Hadengue 1998; Yang 2001; Solanki 2003; Martín-Llahí 2008;
Neri 2008; Pulvirenti 2008; Sanyal 2008; Boyer 2016). One trial
used a cross-over design (Hadengue 1998), and the remaining
a parallel-group design (Hadengue 1998; Solanki 2003; Martín-
Llahí 2008; Neri 2008; Pulvirenti 2008; Sanyal 2008; Zafar 2012;
Boyer 2016).
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Figure 1. Study flow diagram.
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Included studies
Trial characteristics
One RCT was published in abstract form (Zafar 2012) and the
remaining RCTs as full-paper articles (Characteristics of included
studies). The language of trial publications was Chinese (Yang
2001), Italian (Pulvirenti 2008), or English (Hadengue 1998;
Solanki 2003; Martín-Llahí 2008; Neri 2008; Sanyal 2008; Zafar
2012; Boyer 2016). The trialswere conducted in theUnited States,
Italy, Spain, Canada, India, China, Germany, and Russia. The trial
investigators performed the trials in specialised units in an inten-
sive or semi-intensive setting. Three trials were multicenter trials
(Neri 2008; Sanyal 2008; Boyer 2016), and the remaining tri-
als were single-centre trials (Hadengue 1998; Yang 2001; Solanki
2003; Martín-Llahí 2008; Pulvirenti 2008; Zafar 2012).
The duration of follow-up was six months in two trials (Pulvirenti
2008; Sanyal 2008), three months in one RCT (Boyer 2016), and
end of treatment in the remaining trials (Hadengue 1998; Yang
2001; Solanki 2003; Martín-Llahí 2008; Neri 2008; Zafar 2012).
Participant characteristics
The total number of participants was 534 participants. Included
participants had cirrhosis, ascites, and hepatorenal syndrome with
serum creatinine > 133 µmol/L (1.5 mg/dL) after diuretic with-
drawal and volume expansion. None of the participants had evi-
dence of shock, parenchymal renal disease, treatmentwith nephro-
toxic drugs, or other potential causes of kidney disease. In to-
tal, 473 participants had type 1 hepatorenal syndrome. One
RCT included 11 participants with type 2 hepatorenal syndrome
(Martín-Llahí 2008). One RCT with 50 participants did not de-
scribe if participants had type 1 or type 2 hepatorenal syndrome
(Zafar 2012). The mean age in the terlipressin and control groups
ranged from 51 to 59 years and 52 to 60 years. The proportion of
men ranged from 40% to 71%, and the proportion with alcoholic
liver disease from 13% to 72%.
Intervention characteristics
The median initial dose of terlipressin was 1 mg four times daily.
The RCTs used a fixed dose of terlipressin (Hadengue 1998; Yang
2001; Solanki 2003; Pulvirenti 2008), or increased the dose af-
ter three days in non-responders to a maximum of 2 mg four
to six times daily (Martín-Llahí 2008; Neri 2008; Sanyal 2008;
Zafar 2012; Boyer 2016). One trial used continuous administra-
tion of terlipressin for the first day before switching to bolus dos-
ing (Pulvirenti 2008). The duration of terlipressin administration
ranged from two days, in Hadengue 1998, to 19 days, in Neri
2008, with a median treatment duration of 15 days. Two trials
did not use albumin (Hadengue 1998; Yang 2001). All partici-
pants in the experimental and control groups of the remaining
trials received comparable albumin (Solanki 2003; Martín-Llahí
2008;Neri 2008; Pulvirenti 2008; Sanyal 2008; Zafar 2012; Boyer
2016).
Excluded studies
The excluded RCTs compared terlipressin and albumin ver-
sus other vasoactive drugs for hepatorenal syndrome (see
Characteristics of excluded studies).
Risk of bias in included studies
We identified several sources of bias (Figure 2). For the outcome
mortality, we classified one trial as at ’low risk of bias’ Martín-Llahí
2008, and the remaining trials as at ’high risk of bias’ (Hadengue
1998; Yang 2001; Solanki 2003; Neri 2008; Pulvirenti 2008;
Sanyal 2008; Zafar 2012; Boyer 2016). For non-mortality out-
comes, we classified all RCTs as at ’high risk of bias’. No single
study lacked bias across all assessed domains, including randomisa-
tion/sequence allocation, blinding, and for-profit funding sources.
We deemedMartín-Llahí 2008 as at ’low risk of bias’ for mortality
because its sources of bias were only around blinding, which was
less likely to have an influence on a purely objective outcome like
mortality.
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Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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Figure 3 presents review authors’ judgements about each risk of
bias item presented as percentages across all included studies.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Three RCTs did not describe the allocation sequence generation
(Hadengue 1998; Yang 2001; Zafar 2012), and two RCTs did
not describe the allocation concealment (Yang 2001; Zafar 2012).
Accordingly, we classified six RCTs as ’low risk’ of selection bias
(Solanki 2003; Martín-Llahí 2008; Neri 2008; Pulvirenti 2008;
Sanyal 2008; Boyer 2016).
Blinding
We considered tree RCTs that were double-blind as as ’low risk’
of performance and detection bias (Hadengue 1998; Sanyal 2008;
Boyer 2016).We assessed the remaining RCTsas ’unclear’, Solanki
2003, or ’high risk’ of performance and detection bias (Yang 2001;
Martín-Llahí 2008; Neri 2008; Pulvirenti 2008; Zafar 2012).
Incomplete outcome data
Six RCTs had no missing outcome data and included all partic-
ipants in the analyses (Solanki 2003; Martín-Llahí 2008; Neri
2008; Pulvirenti 2008; Sanyal 2008; Boyer 2016). We classified
these RCTs as low risk of attrition bias and the remaining three
RCTs as ’unclear risk’, Yang 2001, Zafar 2012, or ’high risk’ of
attrition bias (Hadengue 1998).
Selective reporting
All RCTs reported clinically relevant outcomes (Hadengue 1998;
Yang 2001; Solanki 2003; Martín-Llahí 2008; Neri 2008;
Pulvirenti 2008; Sanyal 2008; Zafar 2012; Boyer 2016). We iden-
tified no discrepancies between registered protocols (for those
available) and trial publications.
For-profit funding
One RCT did not receive external funding (Martín-Llahí 2008).
Three RCTs received funding from a pharmaceutical company
(Hadengue 1998; Sanyal 2008; Boyer 2016). The remainingRCTs
did not report funding (Yang 2001; Solanki 2003; Neri 2008;
Pulvirenti 2008; Zafar 2012).
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Other potential sources of bias
One study was stopped early due to low event rates (Martín-Llahí
2008).
Effects of interventions
See: Summary of findings for the main comparisonTerlipressin
versus placebo or no intervention for hepatorenal syndrome
Primary outcomes
We were able to gather mortality data from all RCTs (Analysis
1.1). Terlipressin was associated with reduced mortality compared
with placebo/no intervention when including all RCTs (risk ratio
(RR) 0.85, 95%confidence interval (CI) 0.73 to 0.98; 534 partici-
pants; 9 RCTs; I2 = 14%; number needed to treat for an additional
beneficial outcome (NNTB) to prevent one death was 10; low-
quality evidence). In Trial Sequential Analysis including all RCTs
(Figure 4), the cumulative Z-curve did not cross the monitoring
boundary for benefit. We planned to conduct worst-case scenario
analyses. However, as six of the included RCTs did not have miss-
ing outcome data (Solanki 2003; Martín-Llahí 2008; Neri 2008;
Pulvirenti 2008; Sanyal 2008; Boyer 2016), and we were unable
to extract the number of participants with missing outcomes from
the remaining three RCTs (Hadengue 1998; Yang 2001; Zafar
2012), we were therefore unable to conduct the analysis. Subgroup
analyses found an effect of terlipressin in the RCTs evaluating type
1 hepatorenal syndrome (RR 0.78, 95% CI 0.63 to 0.98; 438
participants; 7 RCT; I2 = 30%; Analysis 1.1). We were unable to
gather separate outcome data on participants with type 1 or type
2 hepatorenal syndrome from two RCTs (RR 0.92, 95% CI 0.75
to 1.14; 96 participants; I2 = 0%). An additional subgroup anal-
ysis found no beneficial or harmful effect of the terlipressin and
albumin (RR 0.82, 95% CI 0.67 to 1.01; 510 participants; I2 =
22%; Analysis 1.2).
Figure 4. Trial Sequential Analysis of eight randomised clinical trials (525 participants) evaluating
terlipressin versus placebo or no intervention for people with hepatorenal syndrome on mortality. Data from
Hadengue 1998 is not included due to lack of events. The analysis is made with power 90%, alpha 3%, a relative
risk reduction (RRR) of 25%, a control group risk (CGR) of mortality of 61.5%, and a model variance -based
heterogeneity correction of 30%. The risk ratio is 0.85 (95% confidence interval 0.70 to 1.02). The cumulative
Z-curve (blue line) does not cross the diversity-adjusted trial monitoring boundary for benefit.
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Two RCTs did not report the number of participants without
reversal of hepatorenal syndrome (Hadengue 1998; Yang 2001).
Analysis of the remaining seven RCTs showed a beneficial ef-
fect of terlipressin on this outcome measure (RR 0.63, 95% CI
0.48 to 0.82; 510 participants; I2 = 75%; low-quality evidence;
Analysis 1.3). In Trial Sequential Analysis including these seven
RCTs (Figure 5), the cumulative Z score crossed the monitoring
boundary for benefit.The NNTB to reverse one case of hepatore-
nal syndrome was 4. All RCTs included in this analysis evaluated
terlipressin and albumin. In Trial Sequential Analysis including all
RCTs regardless of bias control (Figure 6), the cumulative Z-curve
crossed the monitoring boundary for benefit. Subgroup analyses
showed a beneficial effect of terlipressin on type 1 hepatorenal
syndrome based on six RCTs (RR 0.64, 95% CI 0.47 to 0.87;
449 participants; I2 = 80%), but not in participants with type 2
hepatorenal syndrome (RR 0.39, 95% CI 0.14 to 1.08; 11 partic-
ipants; 1 RCT) or the trial including participants with type 1 or
type 2 hepatorenal syndrome (RR 0.65, 95% CI 0.46 to 0.92; 50
participants).
Figure 5. Trial Sequential Analysis of seven randomised clinical trials (510 participants) evaluating
terlipressin versus placebo/no intervention for people with hepatorenal syndrome on lack of reversal of
hepatorenal syndrome. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%,
a control group risk (CGR) of lack of reversal of hepatorenal syndrome of 88%, and a heterogeneity correction
of 70%. The risk ratio is 0.64 (95% confidence interval 0.46 to 0.89). The cumulative Z-curve (blue line) crosses
the diversity-adjusted trial monitoring boundary for benefit during the fourth trial.
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Figure 6. Trial Sequential Analysis of four randomised clinical trials (234 participants) evaluating
terlipressin versus placebo or no intervention for people with hepatorenal syndrome on cardiovascular adverse
events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group
risk (CGR) of cardiovascular adverse events of 15%, and a heterogeneity correction of 20%. The risk ratio is
7.26 (95% confidence interval 1.70 to 31.05). The diversity-adjusted trial monitoring boundary for harm is not
included in the figure due to insufficient information. The estimated required information size is 4831
participants. Accordingly, with an accrued number of participants of 234, only 4.8% of the required number of
participants has been achieved.
Overall, terlipressin did not influence the risk of serious adverse
events when analysed as a composite outcome (RR 0.91, 95% CI
0.68 to 1.21; participants = 534; 9 RCTs; I2 = 71%; Analysis 1.4).
The number needed to treat for an additional harmful outcome to
cause one serious adverse event was 24.5. A Trial Sequential Anal-
ysis also found a detrimental effect of terlipressin on this outcome
(Figure 6). As expected, the most common serious adverse events
were cardiovascular (RR 7.26, 95% CI 1.70 to 31.05; Analysis
1.5). Other serious adverse events included circulatory overload,
gastrointestinal bleeding, hepatic encephalopathy, respiratory dis-
tress/acidosis, and bacterial infections.
We repeated the Trial Sequential Analyses with power increased to
90% and the relative risk reduction reduced to 10% for mortality
and 20% for hepatorenal syndrome and serious cardiovascular
adverse events. In the analyses of serious cardiovascular events, we
also reduced the control group risk to 15%. All analyses found
insufficient evidence to support or refute beneficial or harmful
effects of terlipressin versus placebo/no intervention.
Secondary outcomes
None of the included trials assessed health-related quality of life.
Non-serious adverse events were similar when comparing terli-
pressin with placebo or no intervention (RR 1.25, 95% CI 0.58
to 2.68; 406 participants; 5 RCTs; I2 = 17%; Analysis 1.6). The
most frequent adverse events were gastrointestinal, including ab-
dominal pain and diarrhoea.
Quality of the evidence
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We downgraded the quality of the evidence for all outcomes due
to risk of bias, clinical heterogeneity, and imprecision according to
the Trial Sequential Analyses (Summary of findings for the main
comparison).
D I S C U S S I O N
Summary of main results
This review found that terlipressinmay reducemortality andhave a
beneficial effect on renal function in type 1 hepatorenal syndrome,
but an increased risk of serious cardiovascular adverse events was
also noted. Other studies also show that terlipressin may be asso-
ciated with severe adverse effects (Shawcross 2004; Krag 2008),
therefore the intervention should be closely monitored. In addi-
tion, only one RCT had a low risk of bias in the overall assessment
and most of the included RCTs only followed participants to the
end of treatment. Accordingly, the quality of the evidence was low
and additional RCTs may be needed.
The evidence on the use of terlipressin alone and intervention ben-
efits in type 2 hepatorenal syndrome was scarce. Only two of the
included trials assessed terlipressin alone (Hadengue 1998; Yang
2001); the trials were small and the findings were inconclusive.
Likewise, only twoRCTs on terlipressin included participants with
type 2 hepatorenal syndrome (Martín-Llahí 2008; Zafar 2012),
and the number of participants with type 2 hepatorenal syndrome
was relatively small. Accordingly, we identified no clear interven-
tion effects for this patient group.
Overall completeness and applicability of
evidence
We found little evidence of clinical intertrial heterogeneity. The
mean control group Child-Pugh scores were remarkably similar
(11 in three trials) (Martín-Llahí 2008; Neri 2008; Sanyal 2008).
Likewise, the included trials used similar criteria to diagnose hep-
atorenal syndrome, based on previous recommendations (Arroyo
1996). Diagnostic criteria included presence of cirrhosis, ascites,
elevated serum creatinine after at least 48 hours of diuretic with-
drawal and volume expansion combined with absence of shock,
treatment with nephrotoxic drugs, and parenchymal renal disease
(Salerno2007).Updated criteria in 2015nowuse a lower threshold
of increased creatinine to diagnose hepatorenal syndrome (Angeli
2015). Less emphasis is placed on the labels of type 1 hepatorenal
syndrome (defined as serum creatinine increasing to 226 µmol/
L (2.5 mg/dL) within two weeks) and type 2 hepatorenal syn-
drome (defined as a moderate to slowly progressive renal failure
with serum creatinine between 133 and 226 µmol/L (1.5 to 2.5
mg/dL)). Although the included trials used previously established
criteria, the evidence is likely to be applicable today. However, it
may be argued that there is still room for trials on terlipressin using
the current diagnostic criteria, as the current criteria are more sen-
sitive to detection of less severe acute kidney injury. Future trials
would likely benefit from adoption of a standardised treatment al-
gorithm of terlipressin dosing and sample-sized calculations based
on mortality rates, rather than rates of reversal of hepatorenal syn-
drome. Notably, dosing of intravenous terlipressin varied widely
among studies, ranging from 1 mg twice daily, in Yang 2001, to
up to 2 mg six times per day for non-responders in Boyer 2016,
thus making direct comparisons between trials more challenging.
The duration of the effect of terlipressin on mortality should be
considered when deciding whether or not to treat a patient with
hepatorenal syndrome (Gluud 2010). Some participants may die
in spite of a clear improvement in renal function (Martín-Llahí
2008; Sanyal 2008). The duration of treatment varied among
the included trials, ranging from two days, in Hadengue 1998,
to 19 days, in Neri 2008, with a median duration of 15 days.
This may affect the intervention effect estimates. After an initial
complete normalisation of renal function, hepatorenal syndrome
may reappear. We attempted to perform a post hoc analysis to
determine the effect of treatment on recurrence of hepatorenal
syndrome but were unable to extract the necessary data.
Quality of the evidence
The present review identified a number of methodological con-
cerns, including lack of sample size calculations, unclear randomi-
sation, and lack of blinding. We downgraded evidence due to high
risk of bias within individual trials, heterogeneity across trials, and
imprecision (wide confidence intervals) of outcomes. As a result,
the evidence for each of the primary and secondary analyses re-
ceived a low quality rating. One of the included trials reporting
sample size calculations was terminated prematurely due to unex-
pectedly low event rates (Martín-Llahí 2008). The trial assessed
terlipressin plus albumin versus albumin and was terminated after
an interim analysis suggested that 2000 participants would be re-
quired to achieve sufficient statistical power. Whether the interim
results reflect a true (low) intervention effect, a random error, or
the inclusion criteria is difficult to assess. One possible explana-
tion could be that a number of the included participants had type
2 hepatorenal syndrome; overall, there is little evidence on this
patient group.
Potential biases in the review process
One of themain limitations of the present review concerns the rel-
atively low overall sample size. Identification of participants who
clearly fulfil the diagnostic criteria for hepatorenal syndrome may
be difficult, as is the recruitment of critically ill people in clinical
trials. Accordingly, the largest trials were multicentred and multi-
national (Sanyal 2008). This involvement of several clinical sites
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in more than one geographical region increases the clinical het-
erogeneity. On the other hand, the heterogeneity also increases
the external validity, making it possible to extrapolate the results
to larger patient populations in similar specialised centres. The
heterogeneity increases the need for additional subgroup and sen-
sitivity analyses. Analysis of individual patient data would have
increased the possibilities of performing such analyses. Unfortu-
nately, the available data did not allow detailed analyses of poten-
tial sources of heterogeneity. In addition, we have reversed the def-
inition of an event in Analysis 1.3 compared to prior versions of
this review, which resulted in a high event rate, potentially intro-
ducing bias through the use of risk ratios as our effect measure.We
felt the analysis of ’reversal of hepatorenal syndrome’ was easier to
interpret clinically than ’non-reversal’. This also obviated the need
to perform a separate analysis for ’improvement in renal function’.
We did not search specifically for harms reported in quasi-ran-
domised and observational studies, which is a weakness of this re-
view that may bias our assessments of the balance between benefits
and harms.
We did not search databases of regulatory authorities, and so may
have overlookedunpublished trials. This could also have hampered
our assessments of the balance between benefits and harms.
Agreements and disagreements with other
studies or reviews
Three of the included trials found that baseline serum creatinine
was an independent predictor of survival (Martín-Llahí 2008;Neri
2008; Sanyal 2008). In our analyses, the baseline creatinine in the
control groups of the trials on terlipressin plus albumin ranged
from 194 to 362 µmol/L (2.2 to 4.1 mg/dL). All trials found
similar baseline values for the treatment and control groups. In
agreement with previous findings, our analyses suggest that the
treatment effect was the largest in the trial with the lowest baseline
serum creatinine (Solanki 2003). This may suggest that treatment
should be administered early and that a protracted deterioration
in renal function impedes recovery. Inclusion of non-randomised,
observational studies would have increased our ability to detect
rare adverse events. However, we found no observational studies
that reported adverse events to include in these analyses.
A number of meta-analyses have assessed the effect of terlipressin
for hepatorenal syndrome (Fabrizi 2009; Dobre 2010; Sagi 2010).
The results concerning mortality are equivocal. One meta-anal-
ysis found that terlipressin increases survival among participants
with type 1 hepatorenal syndrome (Sagi 2010). The two remain-
ing meta-analyses found no clear effect of terlipressin on survival,
although only one performed ameta-analysis addressing this ques-
tion (Fabrizi 2009). In agreement with our findings, all reviews
found that terlipressin seems to improve renal function but also
increases the risk of cardiovascular and ischaemic adverse events.
The differences between the conclusions in the different reviews
are mainly related to the inclusion criteria. For example, one re-
view only included placebo-controlled trials (Fabrizi 2009). This
decision is not clearly supported by previous evidence on the im-
portance of bias control in RCTs (Gluud 2006; Wood 2008). Al-
though lack of blinding may affect the risk of bias, there is no
clear or consistent evidence to support the exclusion of open tri-
als from meta-analyses since the effect of blinding is inconsistent
across trials. The extent, as well as the effect, of bias associated
with lack of blinding is unpredictable and does not support the a
priori exclusion of trials based on this component alone.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review includes RCTs evaluating people with cirrhosis and
hepatorenal syndrome. The main body of evidence evaluated ter-
lipressin and albumin for participants with type 1 hepatorenal
syndrome. The number of RCTs evaluating terlipressin without
albumin and the number of participants with type 2 hepatorenal
syndrome were small. The analyses suggest a potential beneficial
effect of terlipressin on mortality and hepatorenal syndrome, but
also an increased risk of serious cardiovascular adverse events and
gastrointestinal events such as diarrhoea.
Implications for research
We used the EPICOT format in the definition of implications for
research (Brown 2006):
Evidence (what is the current state of the evidence?): this review
includes seven RCTs and found low-quality evidence that com-
bined terlipressin and albumin has both beneficial and harmful
effects in the management of people with type 1 hepatorenal syn-
drome. Additional research is needed to further evaluate the effect
of the intervention in type 2 hepatorenal syndrome.
Participants (what is the population of interest?): the largest body
of evidence evaluated people with cirrhosis and type 1 hepatorenal
syndrome. Future RCTs should consider evaluating participants
with hepatorenal syndrome defined using current guidelines.
Interventions (what are the interventions of interest?): the inter-
ventions assessed included terlipressin in doses ranging from 1mg
twice a day up to 2 mg six times a day for a median duration of
15 days (range 2 to 19 days).
Comparisons (what are the comparisons of interest?): placebo or
no intervention.
Outcomes (what are the outcomes of interest?): RCTs should in-
clude an assessment of mortality, hepatorenal syndrome, and ad-
verse events. Additional evidence evaluating the effect on health-
related quality of life is also needed.
Time stamp (date of literature search): November 2016.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boyer 2016
Methods Double-blind, multicentre RCT
Participants Participants had cirrhosis and type 1 hepatorenal syndrome based on the 2007 Interna-
tional Club of Ascites criteria
Interventions Terlipressin/albumin versus placebo/albumin for a maximum of 14 days. The investiga-
tors discontinued treatment if serum creatinine was below 1.5 mg/dL at the initiation
of renal replacement therapy or liver transplantation
Terlipressin
• 1 mg 4 times daily increased to 2 mg 6 times daily in non-responders (participants
without improved renal function).
Albumin
• 20 to 40 g/day.
Outcomes Duration of follow-up: 90 days
Country of origin United States and Canada
Inclusion period October 2010 to February 2013
Proportion with type 1 hepatorenal syn-
drome
100%
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel using placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessors using placebo
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Boyer 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the analyses based on
the intention-to-treat principle. Information about
clinical outcomes was available for all participants
Selective reporting (reporting bias) Low risk Clinically relevant outcomes reported as described in
the protocol and online trial registration
For-profit funding High risk Ikaria Therapeutics LLC funded the trial.
Other bias Low risk No other biases identified.
Overall risk of bias (mortality) High risk High risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
Hadengue 1998
Methods Double-blind, single-centre RCT.
Participants • Mean age:
◦ terlipressin group: 53 years
◦ placebo group: 53 years
• Proportion of men: 56%
• Proportion with alcoholic liver disease: 78%
Interventions Terlipressin versus placebo
Terlipressin
• 1 mg twice daily for 2 days.
Outcomes Duration of follow-up: end of treatment
Country of origin France
Inclusion period Not described
Proportion with type 1 hepatorenal syn-
drome
100%
Notes We did not include the trial in our analyses of hepatorenal syndrome because we did not
have information about the outcome measure from the first period
Risk of bias
Bias Authors’ judgement Support for judgement
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Hadengue 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Identical coded drug containers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel achieved
through double-blinding using terlipressin placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment achieved through
double-blinding using terlipressin placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial report states that the analyses excluded 3
participants
Selective reporting (reporting bias) Low risk Clinically relevant outcomes reported.
For-profit funding High risk The trial received funding from Ferring S.A.,
France.
Other bias Low risk No other biases identified.
Overall risk of bias (mortality) High risk High risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
Martín-Llahí 2008
Methods Open, multicentre RCT
Participants • Mean age:
◦ terlipressin/albumin group: 59 years
◦ albumin group: 52 years
• Proportion of men: 63%
• Proportion with alcoholic liver disease: 72%
Interventions Terlipressin/albumin versus albumin for a maximum of 15 days
Terlipressin
• 1 mg 6 times daily. If no improvement in renal function was observed, the dose
was increased to 2 mg 6 times daily.
Albumin
• 1 g/kg for 24 hours then 40 g/day adjusted according to the central venous
pressure.
Outcomes Duration of follow-up: 3 months after treatment
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Martín-Llahí 2008 (Continued)
Country of origin Spain
Inclusion period January 2002 to February 2006
Proportion with type 1 hepatorenal syn-
drome
56%
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel (open trial)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment (open trial)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up, and all participants included in the
analyses
Selective reporting (reporting bias) Low risk Clinically relevant outcome measures reported.
Primary outcome measures:
• mortality after 3 months; and
• improvement in renal function.
For-profit funding Low risk The trial did not receive funding from pharmaceutical com-
panies (reported in the discussion)
Other bias Low risk No other biases identified.
Overall risk of bias (mortality) Low risk Low risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
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Neri 2008
Methods Open, multicentre RCT
Participants • Mean age:
◦ terlipressin and albumin group: 59 years
◦ albumin group: 60 years
• Proportion of men: 40%
• Proportion with alcoholic liver disease: 13%
Interventions Terlipressin/albumin versus albumin for 19 days
Terlipressin
• 1 mg 4 times daily for 5 days then 0.5 mg 4 times daily for 14 days.
Albumin
• 1 g/kg for 24 hours then 40 to 80 g/day.
Outcomes Duration of follow-up: 6 months after hospital discharge
Country of origin Italy
Inclusion period December 2002 to December 2005
Proportion with type 1 hepatorenal syn-
drome
100%
Notes Participants with recurrence of hepatorenal syndrome after the initial treatment received
terlipressin and albumin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel (open trial)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment (open trial)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Selective reporting (reporting bias) Low risk Clinically relevant outcome measures reported.
Primary outcome measure: resolution of hepatorenal syn-
drome defined as normalisation of creatinine
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Neri 2008 (Continued)
For-profit funding Unclear risk Funding not reported. Email requesting information about
funding sent 17 February 2016
Other bias Low risk No other biases
Overall risk of bias (mortality) High risk High risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
Pulvirenti 2008
Methods Open, single-centre RCT.
Participants • Mean age:
◦ terlipressin group: 58 years
◦ albumin group: 61 years
• Proportion of men: 37%
• Proportion with alcoholic liver disease: 13%
Interventions Terlipressin/albumin versus albumin for a maximum of 15 days
Terlipressin
• 1 mg/hour for the first day, then 0.5 mg/8 hours for the next 12 days.
Albumin
• 1 g/kg/day for 5 days.
Outcomes Duration of follow-up: 180 days after treatment
Country of origin Italy
Inclusion period June 2004 to March 2006
Proportion with type 1 hepatorenal syn-
drome
100%
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random numbers
Allocation concealment (selection bias) Low risk Central randomisation
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Pulvirenti 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel (open trial)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment (open trial)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Selective reporting (reporting bias) Low risk Clinically relevant outcome measures reported.
For-profit funding Unclear risk Funding not reported. Email requesting information about
funding sent 17 February 2016
Other bias Low risk No other biases
Overall risk of bias (mortality) High risk High risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
Sanyal 2008
Methods Double-blind, multicentre RCT
Participants • Mean age:
◦ terlipressin/albumin group: 51 years
◦ placebo/albumin group: 53 years
• Proportion of men: 71%
• Proportion with alcoholic liver disease: 36%
Interventions Terlipressin/albumin versus placebo/albumin for a maximum of 14 days
Terlipressin
• 1 mg 4 times daily increased to 2 mg 4 times daily if serum creatinine had not
decreased by at least 30%.
Albumin
• 100 g for 24 hours then 25 g daily.
Outcomes Duration of follow-up: 6 months
Country of origin United States, Germany, and Russia
Inclusion period June 2004 to September 2006
Proportion with type 1 hepatorenal syn-
drome
100%
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Sanyal 2008 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel achieved
through double-blinding using terlipressin placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment achieved through
double-blinding using terlipressin placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analyses including all participants
randomised are reported. No outcomes reported af-
ter censoring
Selective reporting (reporting bias) Low risk Clinically relevant outcome measures reported.
Primary outcome measure: treatment success at day
14 defined as normalisation of serum creatinine on
2 measurements with at least 48-hour intervals and
no dialysis, death, or recurrence of hepatorenal syn-
drome type 1 before day 15
For-profit funding High risk Industry funding (Orphan Therapeutics)
Other bias Low risk No other biases
Overall risk of bias (mortality) High risk High risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
Solanki 2003
Methods Open, single-centre RCT
Participants • Mean age:
◦ terlipressin/albumin group: 51 years
◦ albumin group: 52 years
• Proportion of men: 71%
• Proportion with alcoholic liver disease: 33%
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Solanki 2003 (Continued)
Interventions Terlipressin/albumin versus placebo/albumin for 15 days
Terlipressin
• 1 mg twice daily.
Albumin
• 20 g daily.
Outcomes Duration of follow-up: end of treatment
Country of origin India
Inclusion period Not described
Proportion with type 1 hepatorenal syn-
drome
100%
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table
Allocation concealment (selection bias) Low risk Centralised randomisation through an independent statis-
tician
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors state that the trial is single-blind, but do not
describe the method of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors state that the trial is single-blind, but do not
describe the method of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) Low risk Clinically relevant outcome measures reported.
For-profit funding Unclear risk Funding not reported.
Other bias Low risk No other biases
Overall risk of bias (mortality) High risk High risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
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Yang 2001
Methods Open, single-centre RCT
Participants Participant characteristics (n = 50) not reported.
Interventions Terlipressin versus no intervention for 15 days
Terlipressin
• 1 mg twice daily.
Outcomes Duration of follow-up: 15 days
Country of origin China
Inclusion period Not reported
Proportion with type 1 hepatorenal syn-
drome
100%
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel (open trial)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment (open trial)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear reporting of losses to follow-up
Selective reporting (reporting bias) Low risk Clinically relevant outcome measures reported.
Primary outcome measure: reversal of hepatorenal syn-
drome
For-profit funding Unclear risk Funding not reported.
Other bias Low risk No other biases
Overall risk of bias (mortality) High risk High risk of bias
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Yang 2001 (Continued)
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
Zafar 2012
Methods Open, multicentred RCT.
Participants Participant characteristics not reported.
Interventions Terlipressin/albumin versus albumin for 10 days (range 8 to 12 days)
• Terlipressin (1 mg/4 hourly).
• Albumin (1 g/kg followed by 20 to 40 g/day).
Outcomes Not reported
Country of origin Pakistan
Inclusion period Not reported
Proportion with type 1 hepatorenal syn-
drome
Not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel (open trial)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment (open trial)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk Clinically relevant outcome measures reported.
For-profit funding Unclear risk Not described
33Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zafar 2012 (Continued)
Other bias Low risk No other biases
Overall risk of bias (mortality) High risk High risk of bias
Overall risk of bias (non-mortality out-
comes)
High risk High risk of bias
RCTs: randomised clinical trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alessandria 2007 RCT on noradrenaline/albumin versus terlipressin/albumin for hepatorenal syndrome
Angeli 2008 RCT comparing different modes of administering terlipressin/albumin for hepatorenal syndrome
Cavallin 2012 RCT on terlipressin/albumin versus midodrine/octreotide/albumin for hepatorenal syndrome
Cavallin 2015 RCT comparing terlipressin versus midodrine/octreotide for people with hepatorenal syndrome
Chelarescu 2003 RCT comparing captopril/octreotide versus octreotide published in abstract form
Indrabi 2013 RCT on noradrenalin/albumin versus terlipressin/albumin for hepatorenal syndrome
Nguyen-Tat 2015 Observational study on terlipressin for hepatorenal syndrome
Pomier 2003 Cross-over trial on octreotide for hepatorenal syndrome.
Sharma 2008 RCT on noradrenalin/albumin versus terlipressin/albumin for hepatorenal syndrome
Silawat 2011 RCT on dopamine versus terlipressin/albumin for hepatorenal syndrome
Wan 2014 RCT comparing low and high-dose of terlipressin for hepatorenal syndrome type 1
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Characteristics of ongoing studies [ordered by study ID]
NCT01143246
Trial name or title A placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terli-
pressin
Methods Study type: interventional
Study design: allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator)
Primary purpose: treatment
Participants Cirrhosis, ascites, and hepatorenal syndrome type 1
Interventions Drug: terlipressin
Blinded terlipressin reconstituted with 5 mL of sterile 0.9% sodium chloride solution for injection will be
administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours
(4 mg/day).
Other name: Lucassin
Drug: placebo
Lyophilised mannitol reconstituted with 5 mL of sterile 0.9% sodium chloride solution administered intra-
venously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day)
Outcomes Confirmed hepatorenal syndrome reversal: the percentage of participants with 2 serum creatinine values of
≤ 133 µmol/L (1.5 mg/dL) at least 48 hours apart, on treatment, and without intervening renal replacement
therapy or liver transplant
Starting date September 2010
Contact information Diane Stebbins diane.stebbins@ikaria.com
Notes Estimated enrolment: 180
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D A T A A N D A N A L Y S E S
Comparison 1. Terlipressin alone or with albumin versus no intervention or albumin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 9 534 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.73, 0.98]
1.1 Type 1 hepatorenal
syndrome
7 438 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.63, 0.98]
1.2 Type 1 or 2 hepatorenal
syndrome
2 96 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.75, 1.14]
2 Mortality in randomised clinical
trials evaluating terlipressin and
albumin
7 510 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.67, 1.01]
3 Hepatorenal syndrome 7 510 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.48, 0.82]
3.1 Type 1 hepatorenal
syndrome
6 449 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.47, 0.87]
3.2 Type 2 hepatorenal
syndrome
1 11 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.14, 1.08]
3.3 Type 1 or 2 hepatorenal
syndrome
1 50 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.46, 0.92]
4 Serious adverse events, total
number
9 534 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.68, 1.21]
5 Serious adverse events, types 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Cardovascular adverse
events
4 234 Risk Ratio (M-H, Random, 95% CI) 7.26 [1.70, 31.05]
5.2 Circulatory overload 1 46 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.59, 5.17]
5.3 Gastrointestinal bleeding 1 46 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.22, 2.05]
5.4 Hepatic encephalopathy 1 46 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.68, 1.47]
5.5 Respiratory distress/
acidosis
2 300 Risk Ratio (M-H, Random, 95% CI) 1.97 [0.84, 4.60]
5.6 Bacterial inflections 1 46 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.39, 1.43]
6 Non-serious adverse events 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Total number 5 406 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.58, 2.68]
6.2 Abdominal pain 4 294 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.97, 2.43]
6.3 Chest pain 1 52 Risk Ratio (M-H, Random, 95% CI) 5.00 [0.25, 99.34]
6.4 Livedo reticularis 1 112 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.12, 72.10]
6.5 Diarrhoea 2 240 Risk Ratio (M-H, Random, 95% CI) 5.76 [2.19, 15.15]
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Analysis 1.1. Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome
1 Mortality.
Review: Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Comparison: 1 Terlipressin alone or with albumin versus no intervention or albumin
Outcome: 1 Mortality
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Type 1 hepatorenal syndrome
Boyer 2016 42/97 45/99 18.1 % 0.95 [ 0.70, 1.30 ]
Hadengue 1998 0/4 0/5 Not estimable
Neri 2008 12/26 21/26 9.6 % 0.57 [ 0.36, 0.90 ]
Pulvirenti 2008 8/15 9/15 5.3 % 0.89 [ 0.47, 1.67 ]
Sanyal 2008 32/56 35/56 19.0 % 0.91 [ 0.67, 1.24 ]
Solanki 2003 7/12 12/12 8.8 % 0.60 [ 0.37, 0.97 ]
Yang 2001 0/8 3/7 0.3 % 0.13 [ 0.01, 2.10 ]
Subtotal (95% CI) 218 220 61.3 % 0.78 [ 0.63, 0.98 ]
Total events: 101 (Terlipressin), 125 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.17, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 2.11 (P = 0.035)
2 Type 1 or 2 hepatorenal syndrome
Mart n-Llah 2008 17/23 19/23 18.8 % 0.89 [ 0.66, 1.22 ]
Zafar 2012 19/25 20/25 20.0 % 0.95 [ 0.71, 1.28 ]
Subtotal (95% CI) 48 48 38.7 % 0.92 [ 0.75, 1.14 ]
Total events: 36 (Terlipressin), 39 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 266 268 100.0 % 0.85 [ 0.73, 0.98 ]
Total events: 137 (Terlipressin), 164 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.17, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =5%
0.01 0.1 1 10 100
Favours terlipressin Favours placebo
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Analysis 1.2. Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome
2 Mortality in randomised clinical trials evaluating terlipressin and albumin.
Review: Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Comparison: 1 Terlipressin alone or with albumin versus no intervention or albumin
Outcome: 2 Mortality in randomised clinical trials evaluating terlipressin and albumin
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boyer 2016 0/97 1/99 0.4 % 0.34 [ 0.01, 8.25 ]
Mart n-Llah 2008 7/23 4/23 3.5 % 1.75 [ 0.59, 5.17 ]
Neri 2008 12/26 21/26 15.9 % 0.57 [ 0.36, 0.90 ]
Pulvirenti 2008 8/15 9/15 9.4 % 0.89 [ 0.47, 1.67 ]
Sanyal 2008 32/56 35/56 27.5 % 0.91 [ 0.67, 1.24 ]
Solanki 2003 7/12 12/12 14.8 % 0.60 [ 0.37, 0.97 ]
Zafar 2012 19/25 20/25 28.5 % 0.95 [ 0.71, 1.28 ]
Total (95% CI) 254 256 100.0 % 0.82 [ 0.67, 1.01 ]
Total events: 85 (Terlipressin), 102 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.71, df = 6 (P = 0.26); I2 =22%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours terlipressin Favours placebo
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Analysis 1.3. Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome
3 Hepatorenal syndrome.
Review: Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Comparison: 1 Terlipressin alone or with albumin versus no intervention or albumin
Outcome: 3 Hepatorenal syndrome
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Type 1 hepatorenal syndrome
Boyer 2016 78/97 86/99 20.3 % 0.93 [ 0.82, 1.05 ]
Mart n-Llah 2008 11/17 16/18 14.5 % 0.73 [ 0.49, 1.07 ]
Neri 2008 5/26 21/26 7.0 % 0.24 [ 0.11, 0.54 ]
Pulvirenti 2008 4/15 12/15 6.3 % 0.33 [ 0.14, 0.80 ]
Sanyal 2008 37/56 49/56 18.7 % 0.76 [ 0.61, 0.93 ]
Solanki 2003 7/12 12/12 12.5 % 0.60 [ 0.37, 0.97 ]
Subtotal (95% CI) 223 226 79.3 % 0.64 [ 0.47, 0.87 ]
Total events: 142 (Terlipressin), 196 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.09; Chi2 = 24.40, df = 5 (P = 0.00018); I2 =80%
Test for overall effect: Z = 2.86 (P = 0.0042)
2 Type 2 hepatorenal syndrome
Mart n-Llah 2008 2/6 5/5 5.0 % 0.39 [ 0.14, 1.08 ]
Subtotal (95% CI) 6 5 5.0 % 0.39 [ 0.14, 1.08 ]
Total events: 2 (Terlipressin), 5 (Placebo/No Intervenion)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
3 Type 1 or 2 hepatorenal syndrome
Zafar 2012 15/25 23/25 15.7 % 0.65 [ 0.46, 0.92 ]
Subtotal (95% CI) 25 25 15.7 % 0.65 [ 0.46, 0.92 ]
Total events: 15 (Terlipressin), 23 (Placebo/No Intervenion)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 254 256 100.0 % 0.63 [ 0.48, 0.82 ]
Total events: 159 (Terlipressin), 224 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.08; Chi2 = 28.49, df = 7 (P = 0.00018); I2 =75%
Test for overall effect: Z = 3.46 (P = 0.00055)
Test for subgroup differences: Chi2 = 0.90, df = 2 (P = 0.64), I2 =0.0%
0.01 0.1 1 10 100
Favors terlipressin Favours placebo
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Analysis 1.4. Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome
4 Serious adverse events, total number.
Review: Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Comparison: 1 Terlipressin alone or with albumin versus no intervention or albumin
Outcome: 4 Serious adverse events, total number
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boyer 2016 42/97 45/99 16.2 % 0.95 [ 0.70, 1.30 ]
Hadengue 1998 0/4 0/5 Not estimable
Mart n-Llah 2008 23/23 10/23 13.3 % 2.24 [ 1.42, 3.54 ]
Neri 2008 12/26 21/26 13.4 % 0.57 [ 0.36, 0.90 ]
Pulvirenti 2008 8/15 9/15 10.3 % 0.89 [ 0.47, 1.67 ]
Sanyal 2008 32/56 35/56 16.4 % 0.91 [ 0.67, 1.24 ]
Solanki 2003 7/12 12/12 12.9 % 0.60 [ 0.37, 0.97 ]
Yang 2001 0/8 3/7 1.0 % 0.13 [ 0.01, 2.10 ]
Zafar 2012 19/25 20/25 16.6 % 0.95 [ 0.71, 1.28 ]
Total (95% CI) 266 268 100.0 % 0.91 [ 0.68, 1.21 ]
Total events: 143 (Terlipressin), 155 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.11; Chi2 = 23.79, df = 7 (P = 0.001); I2 =71%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favors terlipressin Favours placebo
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Analysis 1.5. Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome
5 Serious adverse events, types.
Review: Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Comparison: 1 Terlipressin alone or with albumin versus no intervention or albumin
Outcome: 5 Serious adverse events, types
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardovascular adverse events
Mart n-Llah 2008 5/23 0/23 26.2 % 11.00 [ 0.64, 188.13 ]
Neri 2008 3/26 0/26 24.9 % 7.00 [ 0.38, 129.11 ]
Sanyal 2008 3/56 0/56 24.4 % 7.00 [ 0.37, 132.46 ]
Solanki 2003 2/12 0/12 24.5 % 5.00 [ 0.27, 94.34 ]
Subtotal (95% CI) 117 117 100.0 % 7.26 [ 1.70, 31.05 ]
Total events: 13 (Terlipressin), 0 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0075)
2 Circulatory overload
Mart n-Llah 2008 7/23 4/23 100.0 % 1.75 [ 0.59, 5.17 ]
Subtotal (95% CI) 23 23 100.0 % 1.75 [ 0.59, 5.17 ]
Total events: 7 (Terlipressin), 4 (Placebo/No Intervenion)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
3 Gastrointestinal bleeding
Mart n-Llah 2008 4/23 6/23 100.0 % 0.67 [ 0.22, 2.05 ]
Subtotal (95% CI) 23 23 100.0 % 0.67 [ 0.22, 2.05 ]
Total events: 4 (Terlipressin), 6 (Placebo/No Intervenion)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
4 Hepatic encephalopathy
Mart n-Llah 2008 16/23 16/23 100.0 % 1.00 [ 0.68, 1.47 ]
Subtotal (95% CI) 23 23 100.0 % 1.00 [ 0.68, 1.47 ]
Total events: 16 (Terlipressin), 16 (Placebo/No Intervenion)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Respiratory distress/acidosis
Boyer 2016 12/93 7/95 91.7 % 1.75 [ 0.72, 4.25 ]
0.002 0.1 1 10 500
Favors terlipressin Favours placebo
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(. . . Continued)
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sanyal 2008 3/56 0/56 8.3 % 7.00 [ 0.37, 132.46 ]
Subtotal (95% CI) 149 151 100.0 % 1.97 [ 0.84, 4.60 ]
Total events: 15 (Terlipressin), 7 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
6 Bacterial inflections
Mart n-Llah 2008 9/23 12/23 100.0 % 0.75 [ 0.39, 1.43 ]
Subtotal (95% CI) 23 23 100.0 % 0.75 [ 0.39, 1.43 ]
Total events: 9 (Terlipressin), 12 (Placebo/No Intervenion)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
0.002 0.1 1 10 500
Favors terlipressin Favours placebo
42Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome
6 Non-serious adverse events.
Review: Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Comparison: 1 Terlipressin alone or with albumin versus no intervention or albumin
Outcome: 6 Non-serious adverse events
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Total number
Boyer 2016 31/93 35/95 67.9 % 0.90 [ 0.61, 1.34 ]
Neri 2008 6/26 0/26 6.7 % 13.00 [ 0.77, 219.53 ]
Pulvirenti 2008 2/15 2/15 14.4 % 1.00 [ 0.16, 6.20 ]
Sanyal 2008 1/56 0/56 5.4 % 3.00 [ 0.12, 72.10 ]
Solanki 2003 1/12 0/12 5.6 % 3.00 [ 0.13, 67.06 ]
Subtotal (95% CI) 202 204 100.0 % 1.25 [ 0.58, 2.68 ]
Total events: 41 (Terlipressin), 37 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.18; Chi2 = 4.83, df = 4 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Abdominal pain
Boyer 2016 30/93 20/95 89.3 % 1.53 [ 0.94, 2.50 ]
Neri 2008 1/26 0/26 2.1 % 3.00 [ 0.13, 70.42 ]
Pulvirenti 2008 2/15 2/15 6.4 % 1.00 [ 0.16, 6.20 ]
Solanki 2003 1/12 0/12 2.2 % 3.00 [ 0.13, 67.06 ]
Subtotal (95% CI) 146 148 100.0 % 1.54 [ 0.97, 2.43 ]
Total events: 34 (Terlipressin), 22 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
3 Chest pain
Neri 2008 2/26 0/26 100.0 % 5.00 [ 0.25, 99.34 ]
Subtotal (95% CI) 26 26 100.0 % 5.00 [ 0.25, 99.34 ]
Total events: 2 (Terlipressin), 0 (Placebo/No Intervenion)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
4 Livedo reticularis
Sanyal 2008 1/56 0/56 100.0 % 3.00 [ 0.12, 72.10 ]
Subtotal (95% CI) 56 56 100.0 % 3.00 [ 0.12, 72.10 ]
Total events: 1 (Terlipressin), 0 (Placebo/No Intervenion)
0.002 0.1 1 10 500
Favors terlipressin Favours placebo
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(. . . Continued)
Study or subgroup Terlipressin
Placebo/No
Intervenion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
5 Diarrhoea
Boyer 2016 22/93 4/95 89.0 % 5.62 [ 2.01, 15.68 ]
Neri 2008 3/26 0/26 11.0 % 7.00 [ 0.38, 129.11 ]
Subtotal (95% CI) 119 121 100.0 % 5.76 [ 2.19, 15.15 ]
Total events: 25 (Terlipressin), 4 (Placebo/No Intervenion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.54 (P = 0.00039)
0.002 0.1 1 10 500
Favors terlipressin Favours placebo
A P P E N D I C E S
Appendix 1. Search strategies
Database Timespan Search strategy
Cochrane Hepato-Biliary Group Con-
trolled Trials Register
November 2016 (terlipressin* OR glypressin* OR vasoconstric*) AND ’hep-
atorenal syndrom*’
Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Li-
brary
2016, Issue 11 #1MeSHdescriptor Vasoconstrictor Agents explode all trees
#2 terlipressin* OR glypressin* OR vasoconstric*
#3 (#1 OR #2)
#4 MeSH descriptor Hepatorenal Syndrome explode all
trees
#5 hepatorenal syndrom*
#6 (#4 OR #5)
#7 (#3 AND #4)
MEDLINE (OvidSP) 1946 to November 2016 1. exp Vasoconstrictor Agents/
2. (terlipressin* or glypressin* or vasoconstric*).mp. [mp=
title, original title, abstract, name of substance word, subject
heading word]
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(Continued)
3. 1 or 2
4. exp Hepatorenal Syndrome/
5. hepatorenal syndrom*.mp. [mp=title, original title, ab-
stract, name of substance word, subject heading word]
6. 4 or 5
7. 6 and 3
8. (random* or blind* or placebo* or meta-analysis).mp.
[mp=title, original title, abstract, name of substance word,
subject heading word]
9. 8 and 7
Embase (OvidSP) 1974 to November 2016 1. exp Terlipressin/
2. exp Vasoconstrictor Agent/
3. (terlipressin* or glypressin* or vasoconstric*).mp. [mp=
title, abstract, subject headings, heading word, drug trade
name, original title, devicemanufacturer, drugmanufacturer
name]
4. 1 or 3 or 2
5. exp Hepatorenal Syndrome/
6. hepatorenal syndrom*.mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original title, de-
vice manufacturer, drug manufacturer name]
7. 6 or 5
8. 4 and 7
9. (random* or blind* or placebo* or meta-analysis).mp.
[mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug manu-
facturer name]
10. 8 and 9
Science Citation Index Expanded (Web of
Science)
1900 to November 2016 # 5 #4 AND #3
# 4 TS=(random* or blind* or placebo* or meta-analysis)
# 3 #1 AND #2
# 2 TS=(hepatorenal syndrom*)
# 1 TS=(terlipressin* or glypressin* or vasoconstric*)
WH A T ’ S N E W
Date Event Description
17 February 2016 New search has been performed Based on peer review comments, the outcomes now in-
clude health-related quality of life and the total number
of serious adverse events. We now only include trials
with a placebo or no intervention comparison. Trials
with active comparators are included in a separate re-
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(Continued)
view (Israelsen 2015a). We have updated the methods
based on the latest recommendations from Cochrane
and the Cochrane Hepato-Biliary Group. The updates
include the statistical analyses and the bias assessment
17 February 2016 New citation required but conclusions have not
changed
We included three additional randomised clinical trials
(RCTs). Our overall conclusions did not change
C O N T R I B U T I O N S O F A U T H O R S
Two authors (AA and MI) updated the searches, listed potentially eligible trials, and extracted data. Four authors participated in the
final selection of trials (AA, MI, AK, LG), and three conducted the analyses (AA, MI, LG). Three authors (AA, MI, LG) participated
in the interpretation of data and revision of the review. All authors approved the final version.
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External sources
• No external funding received, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We have updated the criteria for assessment of the outcome measures, bias control, and statistical analyses including the Trial
Sequential Analysis.
• Based on the latest criteria (described by the International Club of Ascites (www.icascites.org)) and the recommendation of the
Cochrane Hepato-Biliary Group, we have excluded urine output and creatinine clearance from our analyses.
• We originally planned to include trials comparing different vasoactive drugs, but excluded these analyses based on review
comments.
• In keeping with updates to Cochrane review protocols, we changed the title and objectives to include the term “people with
cirrhosis”, though this did not affect the inclusion of studies.
• We have changed the term “reversal of hepatorenal syndrome and improved renal function” to “number of participants who did
not achieve reversal of hepatorenal syndrome”, in order to be consistent with the other primary outcome (mortality), which is also
framed in the negative. We removed “improved renal function”, as it replicates the same analysis as “reversal of hepatorenal syndrome”.
• We have added calculations of number needed to treat for primary outcomes.
• We have moved health-related quality of life to the secondary outcomes.
• We did not perform Egger’s test to assess the effect of small study size.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Albumins [therapeutic use]; Hepatorenal Syndrome [classification; ∗drug therapy]; Lypressin [∗analogs & derivatives; therapeutic use];
Randomized Controlled Trials as Topic; Vasoconstrictor Agents [∗therapeutic use]
MeSH check words
Humans
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